Deck Bio develops T‑cell engager immunotherapies that bind multiple cancer‑specific peptide‑MHC complexes (pMHCs) to direct immune cells against heterogeneous tumors. Their proprietary dbTCE™ format uses engineered T‑cell receptors (via the dbSCOPE™ platform) to recognize intracellular antigens and maintain activity even as individual targets are lost, while the dbTv™ technology ensures antibody‑like stability and scalable manufacturing.
Funding
Funding not disclosed
Founders
Product
Problem
Current T cell–based cancer therapies often target a single surface antigen, which limits efficacy against heterogeneous tumors and leads to resistance when that antigen is lost or downregulated.
Solution
Deck Bio’s dbTCE™ platform creates multi‑pMHC T cell engagers that simultaneously bind several cancer‑specific peptide‑MHC complexes presented on tumor cells. By engaging multiple intracellular antigens, the engagers activate nearby T cells to kill the tumor even if individual targets are lost, reducing the risk of resistance. The company’s dbSCOPE™ high‑throughput TCR engineering pipeline identifies TCRs with precise pMHC specificity and favorable safety profiles, while the proprietary dbTv™ stabilized binding domain provides antibody‑like stability and manufacturability, enabling scalable production within existing antibody manufacturing infrastructure.
Target Audience
Primary customers are oncology biopharma companies and research programs seeking next‑generation T cell‑engaging immunotherapies for solid tumors with heterogeneous antigen expression.
Features
- Multi‑pMHC binding format (dbTCE™) that targets several peptide‑MHC complexes on a single tumor cell
- Maintains cytotoxic activity despite antigen loss or down‑regulation, addressing tumor heterogeneity
- High‑throughput TCR specificity platform (dbSCOPE™) combines large pMHC libraries, computational analysis, and structural modeling to select precise, safe receptors
- dbTv™ stabilized TCR binding domain offers antibody‑like stability and compatibility with standard antibody production processes
- Modular protein engineering approach enables rapid generation of new engagers for diverse solid‑tumor indications